1. Home
  2. PUBM vs CERS Comparison

PUBM vs CERS Comparison

Compare PUBM & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$8.13

Market Cap

303.6M

Sector

Technology

ML Signal

HOLD

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$1.67

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
CERS
Founded
2006
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
303.6M
276.0M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
PUBM
CERS
Price
$8.13
$1.67
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$18.44
N/A
AVG Volume (30 Days)
813.8K
1.8M
Earning Date
05-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.27
EPS
N/A
N/A
Revenue
$282,926,000.00
$51,326,000.00
Revenue This Year
$3.33
$20.00
Revenue Next Year
$8.29
$9.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.68
52 Week Low
$6.15
$1.12
52 Week High
$13.26
$2.96

Technical Indicators

Market Signals
Indicator
PUBM
CERS
Relative Strength Index (RSI) 56.39 30.59
Support Level $7.97 $1.37
Resistance Level $9.12 $1.72
Average True Range (ATR) 0.46 0.16
MACD 0.08 -0.08
Stochastic Oscillator 63.56 5.19

Price Performance

Historical Comparison
PUBM
CERS

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: